US Bancorp
DMRA icon

US Bancorp’s Damora Therapeutics DMRA Stock Holding History

US Bancorp’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$724 Buy
+34
New +$961 ﹤0.01% 4087

Other funds holding DMRA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

US Bancorp's DMRA Position: Q3 2026 in Review

US Bancorp opened a new position in Damora Therapeutics (DMRA) in Q3 2026: 34 shares worth $724. The stake represents ﹤0.01% of the portfolio and ranks #4087 among its holdings.

21 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • US Bancorp held 34 shares of Damora Therapeutics worth $724 as of Q3 2026.
  • Damora Therapeutics was a new US Bancorp position in Q3 2026.
  • Damora Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #4087 holding.
  • 21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.